Piper Sandler initiated coverage of Merus (MRUS) with an Overweight rating and $84 price target The firm views the company’s EGFRxLGR5 bispecific, petosemtamab, as “significantly de-risked” as both a monotherapy in second-line head and neck squamous cell carcinoma and in combination with pembrolizumab in first-line head and neck squamous cell carcinoma cells that express the PD-L1 protein. Piper expects additional Phase II data on the combo in 2025 to “significantly de-risk” the Phase III LiGeR-HN1 study. It believes petosemtamab is positioned to generate $3B-plus in risk-adjusted revenues by 2035 in head and neck squamous cell carcinoma alone.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Roblox downgraded, Pinterest upgraded: Wall Street’s top analyst calls
- Merus initiated with an Overweight at Wells Fargo
- Biohaven enters multi-target collaboration with Merus
- Biohaven, Merus enter research pact and license agreement to develop three ADCs
- Merus doses first patient in petosemtamab trial